Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDGN201 TARGTEPO · 1 trial · 2 indications
Due to the small sample size and the dispersion of total EPO secretion, the efficacy analyses were performed on all of the patients as a single cohort of intended dose between 25 and 45 U/Kg/d.
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day) |
| Group B | EXPERIMENTAL | MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day) |
| Group C | EXPERIMENTAL | MDGN201 TARGTEPO secreting EPO (55-65 IU/Kg/day) |
| Name | Type | Description |
|---|---|---|
| MDGN201 TARGTEPO | BIOLOGICAL | Erythropoietin secreted by TARGTEPO transduced with MDGN201 |
Inclusion Criteria: 1. For ESRD patients: Subject diagnosed with Anemia due to Chronic Renal Failure CKD stage 5 on hemodialysis treatment for at least 6 months. Average Hb during last month between 9 to 12g/dL. 2. Kt/V \>1 3. INR not higher than 1.2 4. Serum albumin \>3.5 5. Subjects with adequate...
Top 20 of 28 competitors
MDGN201 TARGTEPO is an investigational monoclonal antibody developed by Avalo Therapeutics, Inc. (ticker AVTX) for chronic kidney disease. It was studied in a Phase 1 clinical trial evaluating treatment for anemia in patients with chronic kidney disease and end-stage renal disease. The program is in clinical development and is not approved.
MDGN201 TARGTEPO was studied for the treatment of anemia in patients with chronic kidney disease and end-stage renal disease. The Phase 1 trial enrolled adults aged 18 years and older, including both men and women, in Israel. The study has been completed.
MDGN201 TARGTEPO is being developed by Avalo Therapeutics, Inc., which trades under the ticker AVTX. Avalo Therapeutics is the sponsor of the clinical program for this monoclonal antibody in chronic kidney disease.
MDGN201 TARGTEPO is in Phase 1 clinical development. It is an investigational monoclonal antibody and has not been approved for commercial use. The Phase 1 trial has been completed, and no active trials are currently listed for this program.
MDGN201 TARGTEPO was evaluated in one completed Phase 1 trial, NCT02117427, titled TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD). The trial enrolled 11 participants in Israel and used a controlled design without randomization or double blinding.